416 related articles for article (PubMed ID: 32429706)
1. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; MarinĂ² M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
3. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
Smith TJ
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
[TBL] [Abstract][Full Text] [Related]
4. 2021 update on thyroid-associated ophthalmopathy.
Neag EJ; Smith TJ
J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
Smith TJ
J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
Ali F; Chorsiya A; Anjum V; Ali A
Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
[TBL] [Abstract][Full Text] [Related]
9. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab for the treatment of thyroid eye disease.
Ju Y; Yang J
Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
13. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
Smith TJ
Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JAMJL
Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
[TBL] [Abstract][Full Text] [Related]
16. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
[TBL] [Abstract][Full Text] [Related]
18. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
Douglas RS
Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804
[TBL] [Abstract][Full Text] [Related]
20. Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy.
Smith TJ
Eur Thyroid J; 2020 Dec; 9(Suppl 1):31-39. PubMed ID: 33511083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]